Duragesic Risk Management Plan Under “Discussion”; New Warnings Added

Johnson & Johnson/Alza and FDA are discussing the creation of a risk management program for Duragesic, the agency said in a Feb. 4 letter approving labeling changes for the fentanyl transdermal system